60 Degrees Pharmaceuticals revenue was $1.23M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $528.6k, up 105% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, SXTP annual revenue was $681.3k, with 168.7% growth year-over-year.
SXTP past revenue growth
How has SXTP's revenue growth performed historically?
On Invalid Date, 60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q3 2025 revenue of $528.56 thousand up 256.87% year over year. In the same quarter last year, 60 Degrees Pharmaceuticals's revenue was $148.11 thousand.
What was 60 Degrees Pharmaceuticals's revenue in 2024?
60 Degrees Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $681.35 thousand, a 168.7% increase year over year.
How much does 60 Degrees Pharmaceuticals make in a day?
Based on 60 Degrees Pharmaceuticals annual revenue for the past four years, SXTP makes an average of $4,759.07 per day.
What was 60 Degrees Pharmaceuticals's annual revenue growth in the past year?
As of Q1 2026, 60 Degrees Pharmaceuticals's revenue has grown 314.67% year over year. This is 18.97 percentage points higher than the US Biotechnology industry revenue growth rate of 295.7%. 60 Degrees Pharmaceuticals's revenue in the past year totaled $1.23 million.
How much does 60 Degrees Pharmaceuticals make in a year?
60 Degrees Pharmaceuticals's revenue by year for the past four years is:
60 Degrees Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $681.35 thousand, a 168.7% increase year over year.
60 Degrees Pharmaceuticals's annual revenue for Dec 31, 2023 was $253.57 thousand, a 50.4% decrease from 2022.
60 Degrees Pharmaceuticals's annual revenue for 2022 was $511.21 thousand, a 90.71% decrease from 2021.
60 Degrees Pharmaceuticals's annual revenue for 2021 was $5.50 million, a 197.98% increase from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.